All In Biotech

Drug Trial Radar · NCT00872469

World Maternal Antifibrinolytic Trial

Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial

Last checked: Nov 19, 2026Latest source record: Feb 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 20,060 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20,060

Actual

Start

May 2009

Primary completion

Jun 2016

Study completion Apr 2017

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 31, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The WOMAN trial is a large pragmatic randomised double-blind, placebo controlled trial to quantify the effects of the early administration of tranexamic acid on death, hysterectomy and other relevant outcomes. 20,000 adult women, after delivery who have clinically diagnosed postpartum haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Additionally, TWO nested studies will be conducted in a subset of women trial participants. The first nested study (ETAC) aims to evaluate the effect of tranexamic acid (TXA) on markers of coagulation in 400 women randomised to the WOMAN trial. The second nested study (ETAPLAT) aims to evaluate the haemostatic effect and antithrombotic effect of TXA in 128 women randomised to the WOMAN trial.

Conditions

  • Postpartum Haemorrhage

Interventions

  • Tranexamic acidDrug

    1-2 grams by intravenous injection

  • Placebo [Saline]Drug

    Matched to active comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary outcome is the proportion of women who die or undergo hysterectomy. The primary cause of death will be described.Time frame: up to 42 days after randomisation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University College Hospital

    Ibadan, Nigeria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.